Search Results

aTyr Pharma, Inc. announced that the Company will be changing its ticker symbol from “LIFE” to “ATYR.” Effective at the market open on June 5, 2024, the Company’s common stock will trade on the Nasdaq Capital Market under the new symbol “ATYR.”

aTyr Pharma, Inc. announced that the Compensation Committee of aTyr’s Board of Directors has granted two employees nonstatutory stock options to purchase an aggregate of 9,400 shares of aTyr’s common stock, each with an exercise price of $1.86 per share, which is equal to the closing price of aTyr’s common stock on the Nasdaq Capital Market on May 22, 2024, the effective date of the grants.

aTyr Pharma, Inc. today announced that the company will participate in two upcoming investor conferences scheduled to take place in April 2024.

aTyr Pharma, Inc. announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present at several upcoming investor conferences scheduled to take place in May and June 2024.

aTyr Pharma, Inc., a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, announced first quarter 2024 results and provided a corporate update.

aTyr Pharma, Inc. announced that the company will present data for its lead therapeutic candidate, efzofitimod, at the American Thoracic Society 2024 International Conference, which is scheduled to take place May 17 – 22 in San Diego, CA.

aTyr Pharma, Inc. announced that an independent data and safety monitoring board recommended that the ongoing Phase 3 EFZO-FIT™ study of its lead therapeutic candidate, efzofitimod, in patients with pulmonary sarcoidosis could continue without any modifications after a second pre-planned, interim analysis.